Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

Inclusion Criteria: * Between 20 years old and 85 years old, randomized * Patient who submitted a written informed consent for the this trial * The subjects should be scheduled to have an angiography or intervention through the common femoral artery (CFA). * The subjects must be used a 6Fr sheath of the Terumo's RadiFocus Introducer II. Exclusion Criteria: * In case of the subject has a functure site in both legs. * The patient who had the closing device insertion or manual compression at the targeted femoral artery within 30 days * Patients with severe bleeding disorders (Severe bleeding history, blood coagulation disorder, thrombocytopenia (under 100,000 of platelet count), hemophilia, anemia (Hgb\<10g/dL, Hct\<30%), Thrombasthenia, any related bleeding disorder * Hypertension patient BP ≥180/110mmHg * In case of thrombolysis(ex: streptokinase, urokinase, t-PA) within 24hr * If there is any hematoma, arteriovenous fistula(AVF), false aneurysm existed at the access site of femoral artery * Severe obesity BMI \> 40kg/m2 * In case of prior stent placement or artificial vessel insertion in the common femoral artery(CFA) * Under 5mm of Common femoral artery (CFA) diameter